Jiangsu Gensciences lnc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Jiangsu China (2020)

Organization Overview

First Clinical Trial
2020
NCT04456387
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Haimen Gensciences lnc | Jiangsu Gensciences lnc.

Active Ingredients

Drugs in Phase 3 Trials (1)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (7 trials)

Drugs in Phase 2 Trials (1)

ss109 (2 trials)

Drugs in Phase 1 Trials (1)

antihemophilic factor viii (Recombinant) (Adynovate) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 3